Engineered immune cells take aim at multiple cancers in early trial
NCT ID NCT05035407
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 24 times
Summary
This study tested a new treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack cancer cells with a specific marker (KK-LC-1), and gives them back. It was for adults with advanced stomach, breast, cervical, lung, or other epithelial cancers that have this marker. The main goal was to find the safest dose and see if the treatment shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KITA-KYUSHU LUNG CANCER ANTIGEN 1, HUMAN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.